Can-Fite BioPharma (NYSE:CANF) Stock Rating Upgraded by Zacks Research

Can-Fite BioPharma (NYSE:CANF) was upgraded by research analysts at Zacks Research to a “hold” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

Other equities analysts also recently issued reports about the stock. HC Wainwright set a $5.00 target price on shares of Can-Fite BioPharma and gave the stock a “buy” rating in a research note on Tuesday. D. Boral Capital upgraded shares of Can-Fite BioPharma from a “hold” rating to a “buy” rating in a research report on Wednesday. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $42.50.

Can-Fite BioPharma Price Performance

Shares of CANF stock opened at $3.49 on Wednesday. The firm’s 50-day moving average is $3.36 and its two-hundred day moving average is $4.75. Can-Fite BioPharma has a 12 month low of $2.83 and a 12 month high of $23.40. The company has a market capitalization of $2.29 million, a PE ratio of -1.95 and a beta of 1.09.

Institutional Investors Weigh In On Can-Fite BioPharma

Institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers increased its position in shares of Can-Fite BioPharma by 42.4% during the first quarter. Rhumbline Advisers now owns 38,268 shares of the company’s stock valued at $57,000 after acquiring an additional 11,388 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Can-Fite BioPharma in the fourth quarter valued at approximately $41,000. Finally, Sabby Management LLC grew its holdings in shares of Can-Fite BioPharma by 80.3% in the third quarter. Sabby Management LLC now owns 1,406,050 shares of the company’s stock valued at $871,000 after purchasing an additional 626,306 shares in the last quarter. 21.00% of the stock is currently owned by institutional investors and hedge funds.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company headquartered in Petah Tikva, Israel, that focuses on the development of small molecule drugs for the treatment of inflammatory, oncology and liver diseases. Established in 1994, the company leverages its proprietary technology platform centered on modulating the adenosine receptor system to advance novel therapeutic candidates. Can-Fite’s research and development efforts are directed toward addressing significant unmet medical needs in autoimmune and cancer indications.

The company’s lead product candidates include piclidenoson (CF101) and namodenoson (CF102).